The clinical efficacy of moxonidine in hypertension

Reviews in Contemporary Pharmacotherapy

Volumn 9, Issue 7, 1998, Pages 463-471

  Jager B ^a   Verboom, C ^a   Brunner, H ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HYDROCHLOROTHIAZIDE; LIPID; MOXONIDINE; NIFEDIPINE; THIAZIDE DIURETIC AGENT;

ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; FATIGUE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; INCIDENCE; LIPID BLOOD LEVEL; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; VERTIGO; XEROSTOMIA;

EID: 0031713586     PISSN: 09548602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Allan DR, Penner SB, Smyth DD. Renal imidazoline preferring sites and solute excretion in the rat. Br J Pharmacol 1993; 108: 870-875.
2. Casale PN, Devereux RB, Milner M et al. Value of echocardiographic left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 1986; 105: 173-178.
3. Cohn JN, Levine B, Olivari MT et al. Plasma norepinephrine as a guide to prognosis in patients with congestive heart failure. N Engl J Med 1984; 311: 819-823.
4. Dietrich B, Herrmann WM. Do presynaptic alpha-2 agonists have slighter CNS side effects than postsynaptic agonists? A comparison of moxonidine and clonidine. Eur J Clin Pharmacol 1989; 36 (Suppl): A45-A48.
5. Eichstädt H, Richter W, Bader M et al. Demonstration of hypertrophy regression with magnetic resonance tomography under the new adrenergic inhibitor moxonidine. Cardiovasc Drugs Ther 1989; 3 (Suppl 2): 583-587.
6. Eichstädt H, Gatz G, Schröder R, Kreuz D, Linksventrikuläre Hypertrophie-regression unter einer Therapie mit Moxonidin. Pharmacol Ther 1991; 1: 12-17.
7. 1-imidazoline receptor agonist moxonidine: molecular, cellular and organismic actions. Rev Contemp Pharmacother 1998; 9: 441-462.
8. Feuring M, Cassal D, Stewenov D et al. Safety of moxonidine in patients with mild-to-moderate hypertension and chronic pulmonary disease. Hospitalis 1996; 67: A553.
9. Fliser D, Wijeck A, Ritz E. Renal hemodynamics. Cardiovasc Risk Fact 1995; 5 (Suppl 1): 40-44.
10. Frei M, Küster L, Gardosch-von Krosigk P-P, Koch HF, Küppers H. Moxonidine and hydrochlorothiazide in combination: a synergistic anlihypertensive effect. J Cardiovasc Pharmacol 1994; 24 (Suppl 1): S25-S26.
11. Grahnén A, Wiemann H-J, Wesnes K et al. Acute cognitive effects following addition of single doses of lorazepam to moxonidine/placebo maintenance treatment. J Hypertens 1996; 14 (Suppl 1): S228.
12. 1-imidazoline receptors in the rostral ventrolateral medulla. J Cardiovasc Pharmacol 1994; 24 (Suppl 1): S1-S8.
13. Julius S. Abnormalities of autonomic nervous control in human hypertension. Cardiovasc Pharmacol Ther 1994; 8: 11-20.
14. Julius S. Sympathetic overactivity and the pathophysiology of the coronary risk in hypertension. Cardiovasc Risk Fact 1995; 5 (Suppl 1): 2-10.
15. 2-Adrenozeptor-Agonisten bei Patienten mit arterieller Hypertonie. CorVas 1991; 5: 1-12.
16. Kirch W, Hutt H-J, Plãnitz V. The influence of renal function on clinical pharmacokinetics of moxonidine. Clin Pharmacokinet 1988; 15: 245-253.
17. Kirch W, Hutt H-J, Plãnitz V. Pharmacodynamic action and pharmacokinetics of moxonidine after single oral administration in hypertensive patients. J Clin Pharmacol 1990; 30: 1088-1095.
18. Kraft K, Vetter H. Twenty-four-hour blood pressure profiles in patients with mild-to-moderate hypertension: moxonidine versus captopril. J Cardiovasc Pharmacol 1994; 24 (Suppl 1): S29-S35.
19. Küppers H, Jäger B, Luszick J et al. Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild-to-moderate essential hypertension. J Hypertens 1997; 15: 93-97.
20. Levy D, Garrison RJ, Savage DD et al. Prognostic implications of echocardiographically determined left ventricuar mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-1566.
21. Lotti G, Gianrossi R. Moxonidin vs Captopril bei leichter bis mittelschwerer Hypertonie. Doppelblindstudie zur Wirksamkeit und Verträglichkeit. Fortschr Med 1993; 111: 429-432.
22. MacPhee GJA, Howie CA, Elliott HL, Reid JL. A comparison of the haemodynamic and behavioural effects of moxonidine and clonidine in normotensive subjects. Br J Clin Pharmacol 1992; 33: 261-267.
23. Mill G, Gödde-Salz E, Heidemann HT, Schulte HM. Effects of a new α2-adrenergic agonist moxonidine on anterior pituitary hormone secretion in comparison to clonidine and GHRH. Acta Endocrinologica 1989; 120 (Suppl 1): 80-84.
24. Mitrovic V, Patyna W, Hüting J, Schlepper W. Haemodynamic and neurohormonal effects of moxonidine in patients with essential hypertension. Cardiovasc Drugs Ther 1991; 5: 967-972.
25. 1 receptor agonist moxonidine in patients with idiopathic dilated cardiomyopathy and heart failure. Eur J Clin Res 1996; 8: 149-161.
26. Motz W. Vogt M, Scheler S, Strauer BE. Hypertensive coronary microcirculation - effects of the imidazoline-receptor-agonist moxonidine. Cardiovasc Risk Fact 1995; 5 (Suppl 1): 28-32.
27. Oldenbroek C. Double-blind, placebo-controlled, multicenter parallel group prospectively randomized study of the antihypertensive effects of moxonidine in patients with essential hypertension. Kali-Chemie report 5004. Hannover: Kali-Chemie, 1991.
28. Ongyert D, Dotzer F. Wirksamkeit und Vergräglichkeit von Moxonidin. Z Allg Med 1993; 69: S56-S60.
29. 1-imidazoline preferring receptors: two unique sites mediating natriuresis in the rat. Cardiovasc Drugs Ther 1994; 8 (Suppl 1): 43-48.
30. Pfeffer MA, Pfeffer JM. Reversing cardiac hypertrophy in hypertension. N Engl J Med 1990; 322: 1388-1389.
31. Plänitz V. Crossover comparison of moxonidine and clonidine in mild-to-moderate hypertension. Eur J Pharmacol 1984; 27: 147-152.
32. Plänitz V. Intraindividual comparison of moxonidine and prazosin in hypertensive patients. Eur J Clin Pharmacol 1986; 29: 645-650.
33. Plänitz V, Hoffmann K, Stenzel W. A double-blind crossover trial of moxonidine hydrochloride monohydrate (BF5895) and clonidine hydrochloride in hypertensive patients. Naunyn Schmeidebergs Arch Pharmacol 1984; 325 (Suppl): 84-88.
34. Prichard BNC. Clinical experience with moxonidine. Cardiovasc Drugs Ther 1994; 8 (Suppl 1): 49-58.
35. Prichard BNC, Graham BR. Effective antihypertensive therapy: blood pressure control with moxonidine. J Cardiovasc Pharmacol 1996; 27 (Suppl 3): S38-S48.
36. Prichard BNC, Graham BR. The use of moxonidine in the treatment of hypertension. J Hypertension 1997; 15 (Suppl 1): 47-55.
37. Prichard BNC, Simmons R, Rooks J et al. A double-blind comparison of moxonidine and atenolol in the management of patients with mild-to-moderate hypertension. J Cardiovasc Pharmacol 1992; 20 (Suppl 4): S45-S49.
38. Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
39. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334: 374-381.
40. Rupp H, Jacob R. Excess catecholamines and the metabolic syndrome: should central imidazoline receptors be a therapeutic target? Med Hypotheses 1995; 44: 217-225.
41. Schäfers RF, Philipp T. Moxonidine in hypertension treatment. A clinical summary. Cardiovasc Risk Factors 1995; 5 (Suppl 1): 45-54.
42. Schäfers RF, Löw-Kröger A, Philipp T. Wirksamkeit und Verträgichkeit des neuen zentralwirksamen Antihypertensivums Moxonidin im Vergleich zu Enalapril. Nieren Hochdruckkrankh 1994; 23: 221-224.
43. Schaefer HG, Toublanc N, Weimann H-J. The pharmacokinetics of moxonidine. Rev Contemp Pharmacother 1998; 9: 481-490.
44. Schmidt U, Frerick H, Kraft K et al. Hypertension: a possible risk in road traffic. J Cardiovasc Pharmacol 1992; 20 (Suppl 4): S50-S56.
45. Schwarz VW, Kandziora J. Langzeiterfahrungen mit Moxonidin einem neuen Antihypertensivum. Fortschr Med 1990; 108: 64-70.
46. Schrader J, Schoel G, Gundlach K et al. Antihypertensive Wirkdauer und morgendlicher Blutdruckanstieg unter Moxonidne in der ambulanten 24-Stunden-Blutdruckmessung. Nieren Hochdruckkrankh 1992; 21: 531-533.
47. 1 receptor agonist moxonidine in patients with mild to moderate essential hypertension. Eur J Clin Res 1995; 7: 227-240.
48. 1: an overview of sympathetic receptors involved in blood pressure control targets for drug treatment. J Cardiovasc Pharmacol 1996; 27 (Suppl 3): S5-S10.
49. Van Zwieten PA. Centrally acting antihypertensives: a renaissance of interest. Mechanisms and haemodynamics. J Hypertens 1997:15 (Suppl 1): S3-S8.
50. Webster J, Koch HF. Aspects of tolerability of centrally acting antihypertensive drugs. J Cardiovasc Pharmacol 1996; 27 (Suppl 3): S49-S54.
51. Wenzel RR, Spieker LE, Qui S, Lüscher TF, Noll G. Moxonidine decreases muscle sympathetic nerve activity (MSA) in patients with untreated hypertension. Hospitalis 1997; 67: 1-20.
52. 2-adrenergic agonist, on histamine-induced bronchial constriction and ventilatory occlusion responses to carbon dioxide in asthmatics. 3rd Cardiovascular Pharmacology International Symposium. Kyoto, 1989.
53. Wilkens H, Wilkens JH, Fabel H. Die Wirkung von Moxonidin - einem zentral wirksamen Antihypertensivum - auf Atemregulation und Histaminreaktivität. Kardio 1992; 10: 1-4.
54. Wolf R. The treatment of hypertensive patients with a calcium antagonist or moxonidine: a comparison. J Cardiovasc Pharmacol 1992; 20 (Suppl 4): S42-S44.
55. Zannad F. Trandolapril: how does it differ from other angiotensin converting enzyme inhibitors? Drugs 1993; 46 (Suppl 2): 172-182.
56. Ziegler G, Gemeinhardt A. CNS effects of moxonidine, a new central nervous system anti-hypertensive drug, in comparison with clonidine and placebo. Klin Wochenshr 1988; 66 (Suppl 13): 41-46.
57. 1-imidazoline receptor antagonist. J Cardiovasc Pharmacol 1996; 27 (Suppl 3): S26-S37.